Agilon Health, Inc. Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Ownership Analysis
Agilon Health's ownership story is one of severe value destruction followed by a leadership-led rescue effort. Clayton, Dubilier & Rice backed the company at formation and took it public in 2021. Public investors then absorbed a steep decline as rising medical costs exposed weaknesses in contract pricing and risk management.The company had no controlling shareholder as of 2026. Large institutions hold meaningful voting positions, but the board and executive team determine operating policy. Ronald A. Williams' move into the executive-chairman role in 2025 signaled that the board viewed the situation as a fundamental operating crisis rather than a temporary earnings miss.We view control as dispersed but accountability as concentrated. The board must oversee market exits, payer negotiations and medical-cost forecasting closely. A recovery cannot be judged from membership growth. It requires positive unit economics in the retained markets.For investors, the ownership question is therefore inseparable from execution. Shareholders own the upside if the reset works, but they also bear the risk that the underlying model remains structurally difficult to price.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Agilon Health reported 2025 revenue of approximately $5.93 billion, down about 2%, while membership fell roughly 5% to 625,000. The company recorded a gross loss of about $160 million, a medical margin of negative $57 million, a net loss of approximately $391 million and an adjusted EBITDA loss near $296 million. Those figures show why headline revenue is a poor proxy for shareholder value.Vanguard, BlackRock, State Street and Clayton, Dubilier & Rice were among the largest disclosed holders. Their positions provide voting influence, not operational control. None can fix contract pricing or medical-cost forecasting without action from management and the board.The 2026 investment case rests on whether the reset can turn medical margin positive and move adjusted EBITDA toward breakeven. Management is exiting contracts that cannot earn an acceptable return, seeking improved payer terms and reducing costs. This can make reported scale smaller while improving the economics attributable to shareholders.We would judge progress through medical margin per member, cash use, retained-market performance and the accuracy of guidance. A recovery supported only by revised adjustments or shrinking reserves would not be durable.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Total Care Model | Business | Full-risk Medicare Advantage arrangements with physician partners |
| ACO REACH | Business | Medicare accountable care organization model |
| Physician Partnerships | Business | Long-term partnerships with primary care groups |
| Agilon Platform | Brand | Technology and services platform for value-based care |
Portfolio Analysis
Agilon Health does not rely on a consumer brand portfolio. Its commercial value sits in the Total Care Model, ACO REACH activities, physician partnerships and the Agilon Platform that supports data, contracting and care-management work.The Total Care Model allows established primary care groups to participate in full-risk Medicare Advantage arrangements. Agilon Health supplies capital, analytics and operating infrastructure while physicians maintain the local patient relationship. This creates a less capital-intensive model than owning clinics directly.The Agilon Platform is valuable only if it helps physician partners manage utilization and produce predictable medical economics. Technology, data and support services must translate into better contract performance. Platform scale without risk discipline can magnify losses.We would assess the portfolio through physician retention, market-level medical margins, contract renewal terms and the share of members in profitable arrangements. Those measures reveal more than brand counts or total membership.
Market Share & Competitors
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Agilon Health ★ | N/A | $5.93B FY2025 | Value-based care company partnering with primary care physicians |
| Astrana Health | N/A | N/A | Value-based care and physician-network company |
| Privia Health | N/A | N/A | Physician enablement and value-based care company |
| Alignment Healthcare | N/A | N/A | Medicare Advantage insurer |
| Oak Street Health | CVS Health | N/A | Senior-focused primary care operator |
Competitive Analysis
Agilon Health competes with physician-enablement companies such as Privia Health and Astrana Health, Medicare Advantage-focused insurers such as Alignment Healthcare and clinic operators such as CVS Health's Oak Street Health. These businesses use different asset models, but all must manage the economics of senior care.Agilon Health's main distinction is its partnership approach. It works with established independent physicians instead of buying clinics or employing all clinicians directly. That lowers capital intensity and preserves local trust, but it also requires strong alignment across physicians, payers and the platform.The central competitive challenge is not marketing. It is the ability to forecast medical utilization and secure contract terms that compensate the company for the risk it accepts. Several value-based care peers have struggled with the same problem.We would consider Agilon Health competitively stronger only when retained markets produce consistent positive medical margins and physician partners continue renewing relationships. Growth without those outcomes is not evidence of an advantage.
Acquisitions
Acquisitions Analysis
Agilon Health has expanded mainly through long-term physician partnerships rather than acquisitions. That distinction matters because its growth risk comes from contracts and market entry, not from purchase-price allocation or integration of acquired companies.The partnership model helped the company scale revenue toward $6 billion. It also allowed unprofitable risk arrangements to accumulate when medical utilization rose faster than anticipated. The current strategy reverses part of that expansion through market and contract exits.We see no reason for Agilon Health to prioritize acquisitions during the reset. Capital and management attention should remain focused on pricing, forecasting, payer terms and the economics of the retained physician relationships.Any future transaction should add a capability that improves medical-cost management or contract performance. Buying membership or revenue before the core model reaches sustainable profitability would increase risk rather than create value.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Agilon Health was formed in 2016 with backing from Clayton, Dubilier & Rice and entered the public market in 2021. Its development has not depended on a major merger or spinoff. Organic market launches and physician partnerships created most of the company's scale.This history makes the 2025 reset an operating restructuring rather than a legal reorganization. Management is shrinking or renegotiating exposure inside the existing corporate structure instead of separating a division or combining with another public company.The absence of complex deal history simplifies accountability. Weak results cannot be attributed primarily to acquisition integration. They reflect pricing, medical-cost forecasting and contract selection inside the core model.A sale to a larger healthcare company remains a possible long-term outcome for a distressed public platform, but it is not the current thesis. The near-term task is to establish sustainable economics as an independent company.
Ownership History
Ownership History Analysis
Agilon Health began in 2016 as a private-equity-backed platform designed to help independent primary care physicians move into value-based senior care. Clayton, Dubilier & Rice provided early sponsorship, and the 2021 initial public offering broadened ownership to public investors.The company expanded quickly after the IPO. Revenue and membership grew, but medical utilization from 2023 onward exceeded assumptions embedded in payer contracts. Losses rose and the market value of the public equity fell sharply.In 2025, chief executive Steven Sell stepped down and co-founder Ronald A. Williams assumed the executive-chairman role. Management began exiting structurally unprofitable arrangements, tightening contract standards and concentrating on a smaller core.The ownership record shows that access to public capital and rapid growth did not solve weak risk economics. The next phase depends on whether the company can convert its physician relationships and operating platform into predictable cash-generating contracts.
Ownership Explained
Agilon Health, Inc. is a widely held company listed on the New York Stock Exchange. No shareholder has outright control. Vanguard, BlackRock, State Street and former sponsor Clayton, Dubilier & Rice are among its significant institutional holders.The company partners with independent primary care groups and accepts medical-cost risk through Medicare Advantage and other value-based care arrangements. Its ownership structure gives public shareholders the residual upside and downside from that model.Co-founder Ronald A. Williams became executive chairman during the 2025 leadership reset. The board and management are now reducing unprofitable exposure, tightening contracts and attempting to restore positive medical margins and adjusted EBITDA.
Owning Agilon Health means holding a claim on a value-based care platform whose results depend on pricing medical risk accurately. Revenue alone is not a reliable measure of economic progress because the company can generate billions of dollars while losing money if medical costs exceed the fixed payments it receives.Shareholders therefore need to focus on medical margin, adjusted EBITDA, membership quality and the profitability of individual markets. Exiting an unprofitable contract can reduce revenue and membership while improving the value of the remaining business.The investment case is a high-risk operational recovery. The upside depends on management proving that disciplined pricing and market selection can make the partnership model sustainable. The downside is that medical-cost volatility continues to overwhelm contract economics.